Little Help from Lucentis for Vitreous Hemorrhage (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed.